Company: SRPT
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058003
Chunk: 84

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 84
---
 committee considered the following:

our use of different types of compensation vehicles provides a balance of long- and short-term incentives with fixed and variable components;

our grant of equity-based awards, which generally vest over a four-year time period, encourage our named executive officers to look to long-term appreciation in equity values;

our annual bonus determinations for each employee are dependent on achievement of company goals, which we believe promote long-term value;

the compensation committee’s ability to exercise discretion in determining incentive program payouts and equity awards;

share ownership and holding guidelines applicable to our directors and executive officers; and

prohibition on hedging or pledging of Company stock.

<div align='center'>THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.

58</div>

Compensation Committee Report

The information contained in this report will not be deemed to be “soliciting material,” or to be “filed” with the SEC, or subject to the liabilities of Section 18 of the Exchange Act, nor will such information be incorporated by reference into any future filing under the Securities Act or the Exchange Act, except to the extent that we specifically incorporate it by reference in such filing.

The compensation committee has reviewed and discussed with management the section captioned “Compensation Discussion and Analysis”. Based on our review and discussion, the compensation committee has recommended to the Board, and the Board has approved, that the section captioned “Compensation Discussion and Analysis” be included in the Annual Report on Form 10-K for the year ended December 31, 2024 and this proxy statement for our 2025 Annual Meeting of Stockholders.

<div align='center'>COMPENSATION COMMITTEE

Richard Barry (Chairman)

Kathryn J. Boor, Ph.D.

Deirdre Connelly

Claude Nicaise, M.D.

THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.

59</div>

Compensation Tables Summary Compensation Table The table below summarizes the total compensation paid to or earned by each of the named executive officers for 2024, 2023 and 2022, as applicable (or such shorter period of the named executive officer’s service).

| Name and Principal Position                   |     | Year |     | Salary (1) |         |     | Stock         
 Awards (2)(3) |         |     | Option     
 Awards (2) |             |     |    | Non-Equity       
 Incentive Plan   
 Compensation (5) |           |     | All Other